Prevalence of pulmonary hypertension among the patients diagnosed of Interstitial Lung Disease

Authors

  • Masood Alam Department of Pulmonology, Choudhry Pervez Elahi Institute of Cardiology, Multan – Pakistan
  • Muhammad Imran Sharif Ansari Department of Pulmonology, Nishtar Medical University, Multan - Pakistan
  • Azhar Shehzad Department of Pulmonology, Choudhry Pervez Elahi Institute of Cardiology, Multan – Pakistan
  • Muhammad Imran Shehzad Multan Medical & Dental College, Multan - Pakistan
  • Muhammad Ramzan Department of Pulmonology, Nishtar Medical University, Multan - Pakistan
  • Muhammad Azam Mushtaq Department of Pulmonology, Nishtar Medical University, Multan - Pakistan

DOI:

https://doi.org/10.1996/pjcm.v29i4.782

Keywords:

Interstitial Lung Disease (ILD), Pulmonary Hypertension (PH), Prevalence

Abstract

Background: Exploring the prevalence of pulmonary hypertension (PH) among patients diagnosed with Interstitial Lung Disease (ILD). ILD includes diverse lung disorders characterized by inflammation and fibrosis. PH adds complexity to ILD, affecting severity. Understanding PH frequency in ILD patients is crucial for tailored management. Objective: To observe the Prevalence of pulmonary hypertension among the patients diagnosed with interstitial lung disease.Methodology: This cross-sectional study was conducted at Nishtar Hospital Multan and Choudhry Pervez Elahi Institute of Cardiology (October 1st, 2019, to March 31st, 2020), ILD was identified in 90 participants through HRCT. Patient data, including age, gender, ILD diagnosis date, body mass index, smoking and hypertension history, and presence of pulmonary hypertension, were recorded. Mean and standard deviation are computed for continuous data, while numbers and percentages for nominal data. The chi-square test analyzed the data, classified by gender and hypertension history.Results: Hypertension was present in 21 (23.3%) of all the patients and 14 (15.6%) of the included patients were smokers. Pulmonary hypertension was present in 18 (20.0%) of the patients. On gender distribution, 6 (14.6%) males while 12 (24.50%) females had PH (p=0.244). Among the hypertensive patients, 3 (14.3%) had PH while among normotensive patients, 15 (21.7%) patients had PH (p=0.455).Conclusion: Those who suffer from interstitial lung disease frequently have symptoms of pulmonary hypertension. It is necessary to do clinical research to figure out how to treat pulmonary hypertension because having both interstitial lung disease and pulmonary hypertension is associated with a negative prognosis.

References

Verschakelen JA, De Wever W. Basic anatomy and CT of the normal lung. In Computed Tomography of the Lung. Springer, Berlin Heidelberg, 2018; 3–19.

Zhang G, Zheng X: Practical reviews on the anatomy of the chest. Pract Rev. 2018; 33–54.

Antoniou KM, Margaritopoulos GA, Tomassetti S et al: Interstitial lung disease. Eur Respir Rev, 2014; 23: 40–54.

Burchell RK: Interstitial Lung Diseases. Chapter 32. Gram DW, Milner RJ, Lobetti R (eds.), 2017.

Sisson TH, Mendez M, Choi K et al: Targeted injury of type II alveolar epithelial cells induces pulmonary fibrosis. Am J Respir Crit Care Med. 2010; 181: 254–63.

Hodnett PA, Naidich DP. Fibrosing interstitial lung disease. A practical high-resolution computed tomography–based approach to diagnosis and management and a review of the literature. Am J Respir Crit Care Med. 2013;188(2):141-9.

Caminati A, Cassandro R, Harari S. Pulmonary hypertension in chronic in-interstitial lung diseases. Eur Respir Rev. 2013; 22: 292–301.

Andersen CU, Mellemkjær S, Hilberg O, Nielsen-Kudsk JE, Simonsen U, Bendstrup E. Pulmonary hypertension in interstitial lung disease: Prevalence, prognosis and 6 min walk test. Respir Med. 2012; 106: 875–82.

Cottin V, Le Pavec J, Prévot G, Mal H, Humbert M, Simonneau G, Cordier JF. Pulmonary hypertension in patients with combined pulmonary fibrosis and emphysema syndrome. Eur Respir J. 2010; 35(1): 105–11.

Cottin V, Harari S, Humbert M, Mal H, Dorfmüller P, Jaïs X, Reynaud-Gaubert M, Prevot G, Lazor R, Taillé C, Lacronique J. Pulmonary hypertension in lymphan- gioleiomyomatosis: characteristics in 20 patients. Eur Respir J. 2012; 40: 630–40.

Le Pavec J, Lorillon G, Jaïs X, Tcherakian C, Feuillet S, Dorfmüller P, et al. Pulmonary Langerhans cell histiocytosis- associated pulmonary hypertension: Clinical characteristics and impact of pulmonary arterial hypertension therapies. Chest. 2012; 142: 1150–57.

Nathan SD, Cottin V. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Eur Respir Monogr. 2012; 57: 148–60.

Shlobin OA, Nathan SD. Management of end-stage sarcoidosis: Pulmonary hypertension and lung transplantation. Eur Respir J. 2012; 39: 1520–33.

Cottin V. Treatment of pulmonary hypertension in interstitial lung disease: Do not throw out the baby with the bath water. Eur Respir J, 2013; 41: 781–83.

Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in interstitial lung diseases. Eur Respir Rev. 2017; 26: 160027.

Habash F, Gurram P, Almomani A, Duarte A, Hakeem A, Vallurupalli S, et al. Correlation between echocardio- graphic pulmonary artery pressure estimates and right heart catheterization measurement in liver transplant candidates. J Cardiovasc Imaging. 2018; 26: 75–84.

Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J. 2007; 30(4): 715–21.

Fisher MR, Forfia PR, Chamera E, Housten-Harris T, Champion HC, Girgis RE, et al. Accuracy of Doppler echocardiography in the hemodynamic assessment of pulmonary hypertension. Am J Respir Crit Care Med. 2009; 179: 615–21.

Nathan SD, Shlobin OA, Barnett SD, Saggar R, Belperio JA, Ross DJ, Right ventricular systolic pressure by echocardiography as a predictor of pulmonary hypertension in idiopathic pulmonary fibrosis. Respir Med. 2008; 102: 1305–10.

Núñez B, Sauleda J, Antó JM, Julià MR, Orozco M, Monsó E, et al: Anti-tissue antibodies are related to lung function in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2011; 183: 1025–31.

Medford ARL. Interstitial lung disease and antinuclear antibody: Consider nonspecific interstitial pneumonia histology and newer antibodies. Chest, 2012; 141: 1360–61.

Lv H, Liu J, Pan Q, Cai R, Zhang J. Clinical Retrospective Analysis of Interstitial Lung Disease Patients Associated with Pulmonary Hypertension. Med Sci Mon Int Med J Exp Clin Res. 2019;25:7763-69.

Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL, Chaowalit N, Decker PA. Pulmonary hypertension in patients with idiopathic pulmonary fibrosis. Chest. 2005; 128: 2393–99.

Handa T, Nagai S, Miki S, Fushimi Y, Ohta K, Mishima M. Incidence of pulmonary hypertension and its clinical relevance in patients with sarcoidosis. Chest. 2006; 129: 1246–52.

Shorr AF, Wainright JL, Cors CS, Lettieri CJ, Nathan SD. Pulmonary hypertension in patients with pulmonary fibrosis awaiting lung transplant. Eur Respir J, 2007; 30: 715–21.

Lederer DJ, Arcasoy SM, Wilt JS, D'Ovidio F, Sonett JR, Kawut SM. Six-minute walk distance predicts waiting list survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006; 174: 659–64 29.

Nadrous HF, Pellikka PA, Krowka MJ, Swanson KL. The impact of pulmonary hypertension on survival in patients with idiopathic pulmonary fibrosis. Chest. 2005; 128: 616–17.

Downloads

Published

2023-12-02

How to Cite

Alam, M., Ansari, M. I. S., Shehzad, A. ., Shehzad, M. I., Ramzan, M., & Mushtaq, M. A. (2023). Prevalence of pulmonary hypertension among the patients diagnosed of Interstitial Lung Disease. Pakistan Journal of Chest Medicine, 29(4), 457–461. https://doi.org/10.1996/pjcm.v29i4.782

Issue

Vol. 29 No. 4 (2023)

Section

Original Article

License

Copyright (c) 2023 Pakistan Journal of Chest Medicine

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Most read articles by the same author(s)